ESR1 and breast cancer: The luminal A and B breast cancers are most prevalent subtypes (encompass 60–70% of all breast tumors) with good prognostic value derived from the luminal epithelium of breast ducts and are treated using anti-estrogen therapies (endocrine therapy) that target estrogen-mediated activation of the ER [2].